 By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update IND Cleared to Start Phase 1 Clinical Trial of EPI-7386 On March 31, 2020, ESSA Pharma Inc. NASDAQ:EPIX announced that the company filed an Investigational New Drug IND application with the US FDA and on April 30, 2020, the company received clearance from the FDA to initiate a Phase 1 clinical trial of EPI-7386 